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Abstract
Anemia is one of the most frequent comorbidities found in
patients with coronary artery disease and chronic heart failure
(CHF) who are being followed in cardiac rehabilitation facilities.
The more frequent type of anemia is that caused by iron deficiency
(IDA, iron-deficiency anemia): this review summarizes the state
of the art of this topic. First of all, the mechanisms of IDA will be
analyzed. Subsequently, a description of the main conditions
where IDA can unfavorably affect the clinical course, and of its
more frequent complications, will be presented (percutaneous
interventions, heart surgery, CHF). Special attention will be paid
in the description of anemia in the setting of CHF. To this regard,
in recent years a relevant amount of research has been carried out,
to determine whether treating anemia (either by directly stimulat-
ing erythropoiesis or by correcting iron deficiency by oral or intra-
venous route) is of any clinical and prognostic relevance in
patients with CHF. The results of this research will therefore be
summarized and critically discussed. Finally, we will outline the
promising role of cardiac rehabilitation facilities and of its net-
work of experts in the diagnosis, prognostic stratification and
treatment of anemia and iron deficiency. 
Introduction
Cardiac rehabilitation is a multidisciplinary intervention
aimed at improving the outcome in terms of both the quality of life
and prognosis of patients suffering a broad range of cardiovascular
disease including coronary heart disease, heart failure and valvular
heart disease. The comprehensive approach of cardiac rehabilita-
tion that, apart from exercise, include clinical stabilization, opti-
mization of pharmacological and non-pharmacological treatment,
management of comorbidities and treatment of disability, is
increasingly being appreciated as a successful to manage the com-
plexities of the rapidly growing population of elderly people with
cardiovascular disease [1]. Iron deficiency (ID) and iron-deficien-
cy anemia (IDA) are highly prevalent among patients entering car-
diac rehabilitation programs and are associated with health impli-
cations (including physical decline, cognitive impairment,
increased susceptibility to falling) that may add to the impairment
of the underlying cardiovascular disease or may limit the use of
advanced therapies, as in the examples listed below. The anemia-
associated fatigue and limitation in physical performance in the
post-cardiac surgery patient may not only prolong recovery time
but also negatively impact on quality of life. In coronary artery
disease patients submitted to percutaneous coronary intervention,
anemia is a frequent cause of physician-recommended discontinu-
ation of dual antiplatelet therapy and is associated with an
increased risk of major cardiovascular and bleeding events. In the
context of heart failure, anemia and ID independent of hemoglo-
bin level, besides affecting exercise capacity and symptoms, also
foster the progression of heart failure and a poor outcome. The
mechanisms underlying the detrimental effects of anemia and ID
in heart failure are multifactorial and not fully elucidated. Several
data underscore the role of a further elevation in sympathetic
activity due to the anemia-related tonic activation of excitatory
chemoreceptor afferents [2]. Recent experimental studies point to
the effects of ID on mitochondrial function. In a mouse model of
ID without anemia, ID resulted in decreased left ventricular func-
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tion and a decrease in mitochondrial metabolism [3]. In stem-cell
derived cardiomyocytes, ID was found to impair contractility and
relaxation through compromised mitochondrial respiration [4].
The past twenty years have witnessed a great deal of research in
the field of the pathophysiology of iron homeostasis, and the
development of new iron formulations showing a low rate of
immediate side effects allow to widen the field of application of
iron replacement therapy. Novel diagnostic laboratory analyses
and practical recommendations for the definition, diagnosis and
treatment of ID have been proposed in expert consensus docu-
ments [5]. However, in spite of these recommendations, ID
remains often overlooked and undertreated. Cardiac rehabilitation
facilities are in a privileged position to intercept a large number of
patients who may benefit from iron replacement therapy.
This paper recalls some basic concepts of iron metabolism and
iron-deficiency anemia, summarizes the basic principles of treat-
ment, highlights the size of the problem in the various patients’
populations referred to cardiac rehabilitation, describes the effects
of treatment and discusses how the modern cardiac rehabilitation
should integrate with the treatment of this comorbidity.
Iron metabolism and iron-deficiency anemia:
a definition 
Anemia is a major and global public health problem, affecting
more than 2 billion people and involving all age groups [6]. It is
defined as a hemoglobin (Hb) level <12 g/dl in women and <13 g/dl
in men, and according to Hb levels it is labelled as moderate when
Hb is between 7.0 g/dl and 9.0 g/dl in women and between 8.0 and
10 g/dl in men, and severe when Hb is <7.0 g/dl in women and <8
g/dl in men [6]. 
Epidemiology of anemia varies according to sex, age and
socioeconomic status and is often multifactorial. In elderly patients
one third of cases is due to nutritional deficiency, including iron,
folate and vitamin B12 deficiency. Anemia of chronic disease
(ACD) accounts for about another third of cases. However, in a
proportion of patients, anemia cannot be explained by an underly-
ing disease or by a specific pathological process, and for this rea-
son almost one third of anemia in the elderly is defined “unex-
plained anemia”. 
Half cases of worldwide anemia are due to ID, defined as “a
health-related condition in which iron availability is insufficient to
meet the body’s needs and which can be present with or without
anemia” [7]. Iron is an essential component of Hb in red blood
cells and of myoglobin in muscles and is required for the correct
function of pivotal cellular mechanisms including enzymatic
processes, DNA synthesis and mitochondrial function [8].
Recently, the role of ID itself is emerging as a clinical condition
irrespectively of anemia: ID per se can induce fatigue [9], alter-
ation of cognitive performance and memory [10-12], reduction in
skeletal muscle function and exercise capacity [10], increased risk
of restless leg syndrome [13] and overall impaired quality of life
(QoL) [12]. Adult body contains approximately 4 to 5 grams of
iron: nearly 2 grams are used for red cells synthesis, 300 mg are
used daily in the bone marrow, and approximately 1 gram is stored
in the liver. In a healthy subject the absorption of 1-2 mg per die
balances physiological losses [5,7]. Two forms of ID are outlined
below, absolute ID and functional ID.
Absolute ID occurs when total iron stores are low or depleted.
It is defined by serum ferritin <30 ng/ml and transferrin saturation
(TSAT) <20%. [5]. In chronic diseases a cut-off of ferritin <100
ng/ml is accepted. [5] Either physiological or pathological condi-
tions can cause absolute ID. In infants and young children, due to
the high request of iron for growth, dietary iron can be insufficient
and its storage rapidly depleted. Adolescent girls and women of
childbearing age are at high risk of iron deficiency because of men-
strual losses; during pregnancy iron need is increased due to the
expansion of the maternal red cells and growth of placenta [6]. 
Functional ID is defined by serum ferritin between 100 and 300
ng/ml and TSAT <20% [6]: in this case, iron body stores are normal
or increased, but iron supply to the bone marrow is inadequate often
because of chronic inflammation. Iron homeostasis is controlled by
hepcidin through the internalization of ferroportin, the major iron
external transporter that is expressed on enterocytes, hepatocytes
and macrophages surfaces [15]. When iron level is high, hepcidin is
highly expressed and ferroportin is internalized; thus, iron is trapped
inside enterocytes and lost with their desquamation [15,16]. 
During iron deficiency, hepcidin levels are low, iron can enter
in the blood flow through ferroportin and can be used to form Hb
and other molecules [5,17]. Hepcidin production and release are
increased during inflammation by the activity of circulating
cytokines, especially interleukin6. This results in increased inter-
nalization and degradation of ferroportin and subsequent cellular
iron retention, ultimately leading to decreased levels of circulating
iron and insufficient iron availability [15-17]. 
Basic principles of treatment of ID and IDA 
The treatment of ID and IDA is based on the identification and
control of the cause and on iron supplementation. Iron can be
administered orally, as a ferrous salt (i.e. ferrous sulfate, iron glu-
conate) or intravenously (i.v.) [18]. The choice between oral and
intravenous iron is based on Hb levels, the expected time of cor-
rection of anemia, tolerance to oral iron supplementation and the
presence of concomitant diseases that affect iron absorption: as
discussed below, chronic heart failure is one of such diseases.
Intravenously administration is definitely more effective to correct
IDA. Although its cost is higher than oral supplementation, it
offers several advantages such as rapid repletion of iron stores and
reduction in hospital visits. The ideal iron i.v. product allows the
administration of high amount of iron with low immunogenic risk.
However, in the past, the use of iv iron was limited, due to the
availability of products able to administer high quantity of iron
through highly immunogenic molecules or, conversely, low
immunogenic molecules able to deliver smaller amount of iron. In
the last years, new products with low immunogenic risk and the
ability to administer a high dose of iron in a single dose became
available overcoming an unmet clinical need [17]. Ferric carboxy-
maltose (FCM) is a new iron product that can be administered in
high single doses (up to 1000 mg iron) with rapid infusion (15
min). FCM offers a selective delivery to bone marrow and has a
low immunogenic potential being dextran-free [18]. FCM has
proven safe and rapidly effective in the treatment of IDA in several
settings: heavy uterine bleeding [19], inflammatory bowel disease
[20], chronic kidney disease [21], perioperative anemia [22].
Treatment of ID with FCM has been recommended by the
European Society of Cardiology (ESC) Guidelines for the diagno-
sis and treatment of acute and chronic HF (class IIa, level of evi-
dence A), even in absence of anemia [23], as discussed below.
Despite these treatment options and the advice Choosing Wisely
Campaign: don’t transfuse red blood cells (RBCs) for IDA without
hemodynamic instability of the American Association Blood Banks
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(AABB) [24], patients with chronic IDA are still frequently trans-
fused. Some additional considerations are warranted. First,
notwithstanding AABB guidelines recommendations against
transfusions in hospitalized hemodynamically stable adults includ-
ing critically ill and cardiac surgery patients, RBCs transfusion
remains a frequent hospital procedure at high risk of inappropriate-
ness [25]. Second, despite the reduction of transfusion-related
infection due to specific tests for known agents, exposure to trans-
fusion carries several other risks, including transfusion-related cir-
culatory overload and acute lung injury, allergic reaction, alloim-
munization, immune suppression. Last but not least, transfusion
has a high economic and social cost (Box 1).
Relevance and management of ID and anemia
in cardiac patients in different settings
Acute coronary syndromes and percutaneous coronary
interventions 
In patients with acute coronary syndromes (ACS) prevalence of
anemia ranges between 10 and 32%; in many trials, anemia is an
independent risk factor for increased long term mortality and major
cardiac events [26]. Anemic patients undergoing percutaneous
coronary interventions (PCI) are at higher risk for both ischemic
and bleeding events, with a need of change in dosage, timing and
duration of antithrombotic therapy [27]. When present, anemia
decreases O2 delivery and the consequent increase in cardiac out-
put, leading to chronic tachycardia, exercise myocardial ischemia
and jeopardizing myocardial vitality, thus favoring adverse remod-
eling [28]. In anemic patients, more vulnerable plaques are
observed, characterized by higher burden of necrotic core and thin
cap fibroatheroma. If anemia is caused by bleeding, dual
antiplatelet therapy has to be discontinued prematurely and this can
lead to stent thrombosis and obviously worse outcome. [29]. Of
note, in ACS anemia is also a marker of comorbidities as age, dia-
betes, chronic kidney failure and autoimmune diseases. In patients
suffering from ACS, perhaps aggravated by an accompanying con-
tractile impairment, guidelines are more focused on priorities such
as the need for pharmacological and mechanical support [30] and
the interventional approach, so that the management of anemia is
poorly defined: the management of the anemic patient is based on
optimization and stabilization of the circulation through the use of
transfusions (with a liberal level of hemoglobin <9.0 g/dl) without
standardized modalities. Indeed, a recent study showed that ID in
the setting of ACS is strongly associated with adverse outcome
[31]; therefore, a treatment addressed to solve any ID condition
would sustain energy mechanisms and limit the risk of post-proce-
dural anemia and the consequent need for transfusions.
Cardiac surgery 
Anemia is a frequent condition in cardiac surgery, its overall
prevalence being 25-30% [32,33] with a slight prevalence in males
[32]. Since the most important cause of surgical anemia is hospital-
induced anemia [33], in most patients the preoperative anemia is
preventable. Patients with preoperative anemia have reduced red
blood indices (i.e. mean corpuscular hemoglobin and/or mean cor-
puscular volume); patients with reduced cell indices are younger,
show lower perioperative hemoglobin and have higher transfusion
rates compared to those with normal red cell indices [33]. As in
non-cardiac surgery, in cardiac surgery anemia is linked to surgical
mortality and morbidity; however, the type of surgery (cardiac vs
non-cardiac) and the presence of cardiovascular disease in patients
undergoing general surgery carry an increased mortality risk [33].
Since anemia is often associated with other comorbid conditions, as
chronic kidney disease, older age and poor left ventricular function,
its role as an independent risk factor has not been established [31-
35]: as a consequence, preoperative anemia is not included in risk
scores such as Euroscore [36] but hematocrit is present in STS [37].
Anemia leads to higher transfusion rates; in some reports, even the
transfusion of a single RBC unit led to increased morbidity and
mortality, the risk increasing with transfusion of more units [38]; in
others, transfusion of 1-2 units of red blood cells did not increase
mortality but was associated with an increased risk of acute kidney
insufficiency, sternal wound infection, stroke, prolonged ICU and
in-hospital stay and prolonged mechanical ventilatory support [39].
There is agreement on the concept that perioperative red blood cell
transfusion of more than two units represents the single factor most
reliably associated with increased risk of morbid events after coro-
nary artery bypass grafting [40]. Engoren et al. [41] discriminated
whether anemia, transfusion or the inflammatory state linked to
these two conditions was the real dangerous factor, considering 4
groups of patients: anemic and transfused patients had the highest
death hazard, patients who were not anemic and had not been trans-
fused had the lowest hazard, patients anemic but not transfused and
patients transfused but non-anemic had intermediate death hazard.
Prognosis worsened when major bleeding or preoperative chronic
kidney disease were associated with anemia and/or transfusion.
[42]. Thus, preoperative correction of iron deficiency by intra-
venous iron might be beneficial through the correction of ID per se
or through the correction of anemia [43]. In conclusion, anemia is
not an innocent bystander, on the contrary it represents a con-
traindication to elective procedures and should be managed before
their performance, as detailed below [44]. 
The invasiveness and traumatic effects of surgical interventions,
through a cascade of inflammatory responses [45,46] influence the
volume of blood loss [47] that may in turn be amplified by the over-
lap of coagulopathies that further promote bleeding [48]. A typical
example is cardiac surgery, where extracorporeal circulation (ECC)
modifies the coagulation function. ECC requires a reversible, phar-
macologically-induced anticoagulation state [49]. However, several
factors such as residual heparin effect, reduced thrombin generation,
fibrinogen deficiency, thrombocytopenia, platelet dysfunction and
hyperfibrinolysis could be present in the postoperative phase and
cause a propensity to bleeding [50], whose entity will determine the
extent of patient’s anemic response [50]. The reduced hemoglobin
concentration in healthy patient is compensated by an increase in
cardiac output to ensure adequate tissue O2 delivery [52,53]. In
patients with cardiac disease, this compensatory function is often
inadequate [54] leaving them vulnerable to low levels of circulating
hemoglobin (Hb). Thus, even if international guidelines recommend
restrictive transfusion criteria (Hb 7.0 g/dl), they acknowledge the
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Box 1 - Why transfusions are to be avoided?
RBCs transfun are at high risk of inappropriateness 
Exposure to transfusion carries risk of 
•     transfusion-related circulatory overload and acute lung injury;
•     allergic reaction;
•     alloimmunization; 
•     immune suppression. 
Transfusion has a high economic and social cost
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fragility of cardiac patients and consent to transfuse them at higher
hemoglobin levels (Hb 8 g/dl) [55-58]. The high risk of bleeding and
anemia increase the risk of postoperative transfusion in patient
undergoing cardiac surgery. Preoperative anemia is a modifiable risk
factor [59] for increased postoperative transfusion [60], so that its
correction can reduce the incidence of negative outcomes [61].
Following WHO anemia definition [62], anemia affects about 27%
of the world’s population. A slightly higher prevalence is found in
patients scheduled for cardiac surgery (≈30%), in whom we may
expect an additional blood loss in the perioperative period [63].
Moreover, women are subject to greater blood loss and more trans-
fusions than men undergoing similar procedures [64]. Thus, from the
surgeon’s point of view a hemoglobin level <13 g/dl is inadequate
for both sexes, and 40% the cardiac surgery population would have
suboptimal Hb values that should be treated in a surgical preparation
program. Such aggressive approach has been suggested by a recent
international consensus document regarding Patient Blood
Management (PBM) [65]. The most frequent anemia found in
patients scheduled for cardiac surgery is ID anemia [66,67], fol-
lowed by anemia accompanying kidney disease [68,69]. Around
three to four weeks before surgery, an appropriate screening of the
iron status helps to recognize anemia and look for its etiology, allow-
ing adequate treatment [65]. The increase in preoperative hemoglo-
bin would minimize the loss expected in the postoperative period
[68,69], lessen the two nadirs of hemoglobin (during ECC and in
intensive care), prevent the need for transfusions [70,71]. 
Remarkably, when anemia is observed after surgery in a post-
surgical rehabilitation setting, it does not contraindicate or hinder
rehabilitation programs. In a study by Ranucci et al. [26], hemo-
globin levels of 8 to 10 g/dl at the admittance in Rehabilitation
were associated to a transient impairment of exercise tolerance
(measured by 6-min walking test) directly proportional to the
severity of anemia; this functional gap completely recovered dur-
ing the rehabilitation period. Thus, anemia does not contraindicate
rehabilitation even if anemic patients have a slow recovery in their
physical performance with respect to non-anemic patients; in fact,
the same Authors showed that blood transfusion in the rehabilita-
tion setting did not increase exercise tolerance at the 6-min walk-
ing test [72]. These conclusions have been confirmed by a recent
study, where the Authors showed a high prevalence of ID and a
10% ID anemia in the setting of post-surgical rehabilitation, and
suggested that the rehabilitation phase may be suitable for screen-
ing and correction of ID and ID anemia [73].
Heart failure 
Anemia and ID often coexist in patients with chronic heart fail-
ure (CHF). Both conditions, together or independently, are associ-
ated with poor clinical status and worse outcome. 
Knowing anemia etiology is fundamental to treat it in the best
possible way. As detailed above, iron deficiency and inflammation
play a pivotal role, but heart failure anemia may have additional
causes: 
i) reduced intestinal iron absorption due to abnormal hepcidin
and ferroportin activity in gut cells; 
ii) increased cytokine levels, causing bone marrow blood cells
underproduction;
iii) activation of renin-angiotensin-aldosterone system, determin-
ing hemodilution through sodium and water retention;
iv) reduced erythropoietin (EPO) production due to kidney failure
and at least in part to angiotensin converting enzyme inhibitors
treatment;
v) the use of antiplatelet or anticoagulant agents and the conse-
quent risk of bleeding.
Whether anemia and ID are just markers of HF severity or
whether they mediate HF progression and outcomes is not entirely
clear [74,75]. As stated above, ID in patients with HF can be
absolute or functional, and even in the absence of anemia, absolute
or functional ID represents a major contributor to exercise intoler-
ance and an independent predictor of outcome [75,76]. Although ID
is highly prevalent in patients with CHF, this condition is often neg-
lected because symptoms related to ID and those related to CHF
(fatigue and weakness, dyspnea) may overlap: only the assessment
of plasmatic iron parameters allows ID diagnosis. Regardless of its
causes, high prevalence of ID in CHF has been reported in many
cohorts of patients, ranging from 37% (32% in non-anemic patients)
[75] and 50% (46% in non-anemic patients) [76,77]. The current
European Society of Cardiology guidelines [23] suggest a periodical
assessment of ferritin, transferrin, iron plasma levels and transferrin
saturation (TSAT) in CHF patients, together with the search for the
cause of ID and anemia. Treatment for ID involves the restoration of
iron stores to normal levels and the increase of hemoglobin values,
as well as addressing its underlying causes [23]. 
Anemia and ID status have different therapeutic possibilities:
blood transfusions in acute and hemodynamically unstable
patients, erythropoiesis-stimulating agents and iron replacement,
either oral or intravenous, in chronic patients. The use of erythro-
poiesis-stimulating agents, albeit initially promising [78], has been
abandoned and is currently not recommended [23]. Iron replace-
ment is the treatment of choice. However, oral iron preparations
do not seem effective in patients with HF with reduced ejection
fraction (HFrEF). In the IRONOUT-HF trial, oral iron polysaccha-
ride supplementation did not improve exercise capacity or quality
of life scores, as assessed by Kansas City Cardiomyopathy
Questionnaire (KCCQ) [79]. 
Among the several intravenous iron preparations available in
Europe, FCM has been largely experienced in HF in two large trials:
the “Ferinject Assessment in Patients with Iron Deficiency and
Chronic Heart Failure (FAIR-HF)” (n=459) [80] and “A Study to
Compare the Use of Ferric Carboxymaltose With Placebo in Patients
With Chronic Heart Failure and Iron Deficiency (CONFIRM-HF)”
(n=301) [81]. The FAIR-HF study was as a multicenter, prospective,
double-blind, randomized, placebo-controlled trial [80]. Symptoms,
functional capacity and QoL were significantly improved after treat-
ment with IV FCM in patients with chronic HF and ID, with or with-
out anemia. The CONFIRM-HF trial [81] included 301 patients with
moderate HF (NYHA Class II-III), left ventricular EF (LVEF)
≤45%, increased levels of BNP >100 pg/mL and/or NT-proBNP
>400 pg/mL, and ID. IV iron was given as an FCM solution equiv-
alent to 500 or 1,000 mg of iron. At week 24, the 6MWT distance
improved significantly more in the FCM group; the benefit was
maintained up to 52 weeks. Fatigue and QoL scores also improved
significantly up to week 52, as well as NYHA class and patient glob-
al assessment scores. Furthermore, FCM was associated with a sig-
nificant reduction in the risk of hospitalization due to worsening HF.
Of note, in a sub analysis of the FAIR-HF trial by Ponikowski et al.
[82], FCM treatment was associated with an improvement in renal
function across the entire spectrum of HF patients enrolled in the
trial. This result was present also in the CONFIRM-HF trial [81].
Finally, the recent EFFECT-HF trial (Effect of Ferric
Carboxymaltose on Exercise Capacity in Patients with Iron
Deficiency and Chronic Heart Failure) [83] demonstrated an
improvement in VO2max in 172 symptomatic HFrEF patients treat-
ed with FCM in comparison with the placebo group. 
In addition, meta-analyses confirmed these results [84,85]: for
instance, IV iron therapy in ID patients with systolic HF induced a
significant reduction in the combined endpoints of all-cause death
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or cardiovascular hospitalizations, cardiovascular death or hospi-
talization for worsening HF; moreover, a significant reduction in
NYHA class, an increase in the six-minute walking test (6MWT)
distance, and an improvement in QoL were reported [84].
Following these evidences, the 2016 HF ESC guidelines [77] and
the 2017 ACC/AHA/HFSA update of the 2013 ACCF/AHA guide-
lines for the management of heart failure [86] recommend treat-
ment with FCM in HF patients with iron deficiency who remain
symptomatic despite optimal therapy, in order to alleviate symp-
toms, improve exercise capacity and quality of life (classes of rec-
ommendations and level of evidence: IIa A and IIb B, respectively,
in European and American guidelines). 
So far, it is unclear whether iron therapy affects patients with
midrange and preserved left ventricular ejection fraction, since
most trials excluded patients with left ventricular ejection fraction
greater than 45% [87]. The ongoing FAIR-HfpEF trial (Effect of
IV Iron in Patients with Heart Failure with Preserved Ejection
Fraction; NCT03074591) will assess whether FCM treatment can
improve exercise capacity, by changes in 6MWT distance, in HF
patients with left ventricular ejection fraction above than 45%.
Another ongoing trial will investigate the gray area of acute heart
failure: the AFFIRM-AHF (Study to Compare Ferric
Carboxymaltose with Placebo in Patients with Acute Heart Failure
and Iron Deficiency; NCT02937454) will randomize patients with
left ventricular ejection fraction <50% after acute care treatment.
Furthermore, other trials will increase the information in patients
with HFrEF, such as the FAIR-HF2 (Intravenous Iron in Patients
with Systolic Heart Failure and Iron Deficiency to Improve
Morbidity and Mortality; NCT03036462) or IRON-MAN
(Intravenous Iron Treatment in Patients with Heart Failure and Iron
Deficiency; NCT 02642562). Figure 1 illustrates the  studies cur-
rently ongoing on IV iron treatment for ID and IDA in various
forms of heart failure.
Most CHF patients are not hospitalized for cardiac rehabilita-
tion but are followed in outpatients’ specialized HF units. How can
we organize the quest for ID and ID anemia in this setting? Real-
world data on the efficacy of intravenous FCM therapeutics in cur-
rent clinical practice are still scarce [88-90]. Clinical trials have
typically evaluated patients aged 65.70 years, excluding those with
co-morbidities. To this regard, a single-center double-blind ran-
domized pilot study on 70 patients from a rehabilitation center in
Milano showed the feasibility and reliability of IV iron replace-
ment with FCM [91]. Anemia and ID were defined with usual cri-
teria [77]. Patients underwent symptoms evaluation, blood tests
and cardiopulmonary exercise test before, one month and three
months after IV iron therapy, targeted to replenish iron stores;
NYHA class and peakVO2 at cardiopulmonary test improved only
in the active arm group (Figure 2). From this experience, one may
conclude that treatment of iron deficient anemia is feasible and
easy to organize in an outpatients’ setting, and likely to afford a
significant clinical benefit to chronic heart failure patients.
However, we must take care in not to over-treat patients, since
this may determine an increase of oxidative stress, increasing lev-
els of malondialdheyde and asymmetric dimethylarginine, a bio-
marker of lipid peroxidation and one of the most important agents
causing endothelial dysfunction, respectively [92,93].
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Figure 1. An overview of the studied researches on ID and IDA.
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Key role of cardiac rehabilitation in the diagnosis
and treatment of ID and IDA 
Anemia and iron deficiency may potentially affect all patients
during cardiac rehabilitation (CR) programs, regardless of pri-
mary condition for referral, with high prevalence rates and strong
association to disease severity, as far as to worse outcomes
[94,95]. Anemia and ID also contribute to impaired functional
capacity [87] and increased disability [96]. It seems therefore rea-
sonable to search for and treat ID and IDA, especially in the set-
ting of phase II CR activities. 
During the past recent years, anemia and IDA have emerged as
highly frequent comorbidities in several subsets of patients enter-
ing phase II cardiac rehabilitation. Optimization of therapy (and
accordingly the diagnostic work-up preceding the treatment) is one
of the core components of a modern and multidisciplinary cardiac
rehabilitation. Thus, we believe that phase II cardiac rehabilitation
that usually lasts from three to six weeks and, in addition to phys-
ical training, involves continuous monitoring of patients’ clinical
status and treatment optimization, may in fact offer a valuable
opportunity to comprehensively manage all those clinical condi-
tions that can negatively impact recovery, quality of life and even-
tually physical functioning. Such approach would be appropriate
especially in patients with chronic heart failure (CHF), where ID
and IDA have been extensively investigated, leading to the current
recommendations of the 2016 ESC guidelines [77].
Indeed, a modern CR program - where modern indicates the
care of highly complex and frail patients - would be expected to
consider ID and ID anemia as important determinants of the reha-
bilitative outcome, in terms of i) clinical stabilization; ii) reduc-
tion of exercise intolerance; and iii) promotion of better quality of
life. Noticeably, such an approach should also take into account
the different modalities of presentation of patients (e.g. patients
with recent hospitalization in acute wards due to hemodynamic
instability, or patients in the “vulnerable phase” after index
events, or patients in the chronic phase) and the different CR set-
tings (residential, out-patient, or home-rehabilitation). 
The definition of symptomatic patient should also be inter-
preted in a holistic way - rather than just a grading of dyspnea and
derived NYHA class - in order to integrate detailed information
on functional capacity and fatigue: many of these direct and indi-
rect evaluations are routinely performed during CR activities and
could help identifying appropriate candidates for the intensive
correction of ID and ID anemia. Indeed, intravenous FCM, in
appropriately selected subjects and at the appropriate time, may
boost the efficacy of physical training, due to its documented
effects on muscle metabolism; in this perspective, the CR setting
could really demonstrate the efficacy of such a composite thera-
peutic strategy [73,91] (Box 2). Nonetheless, several features of
this strategy are still controversial, so that we do not have so far a
clear indication for routine practice. 
First, we should identify the proper timing for ID evaluation
during the CR program; as an example, is it appropriate in patients
fast-tracked from acute wards, often presenting with persistent
symptoms of fluid retention? 
Second, we need to organize and implement a proper follow-
up of patients actively treated for ID and IDA: to this regard, ESC
guidelines do not provide adequate recommendations. 
Moreover, how do we define partially and no-responder
patients? Which amount of increase in exercise tolerance clini-
cians could reasonably expect by correcting ID and IDA, and how
to define positive and negative outcomes? 
Finally, there is strong need of a detailed cost-effectiveness
analysis, specifically tailored on CR activities with special regard
on the residential setting. 
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Figure 2. A) NYHA class improved in the active arm group from baseline (visit 1) to visits 2 and 3. B) PeakVO2 at cardiopulmonary test
slightly improved (about 1.5 mL/Kg/min) in the active arm group and remained unchanged in the control group.
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